Brian Hoh
University of Florida, FL·Medicine & Clinical Research
Bleeding and blockages in the brain's blood vessels cause death and lasting disability, and many promising treatments have failed in patients. These projects tackle that problem at three stages.
- Fields
Medicine & Clinical Research
Neuroscience
Pharmacology
- Topics
subarachnoid hemorrhage
stroke
cerebral vasospasm
- Grants
- 3 known grants, through Jun 2031
What they work on
- Determine whether tocilizumab, an antibody blocking the IL-6 receptor, or resveratrol, a SIRT1 activator, improves neurological outcome after subarachnoid hemorrhage in a three-site, blinded, randomized animal trial.
- Compare safety events and cerebral infarcts across animal ages, sexes and coexisting conditions to make a go/no-go decision for a phase 3 human trial.
- Test whether the peptide hormone adropin protects against brain injury after subarachnoid hemorrhage when given at a clinically translatable time point in mice.
- Identify what regulates expression of Enho, the gene that encodes adropin, after hemorrhage, and test whether adropin's protection works through eNOS, the enzyme that makes nitric oxide.
- Test in a 1,683-patient adaptive trial whether ticagrelor or low-dose rivaroxaban, each with aspirin, beats clopidogrel plus aspirin at preventing stroke and vascular death in sICAS.
- Estimate how CYP2C19 loss-of-function gene variants, which impair clopidogrel activation, change the benefit of ticagrelor or rivaroxaban compared with clopidogrel.
More about the research
A basic science project probes a natural brain-protective hormone. A preclinical network tests drugs in animals using the rigor of a human trial. A large clinical trial compares blood-thinning drugs to prevent stroke.
Why it matters
Patients who survive brain bleeds often suffer strokes, disability and long-term cognitive problems, with few proven treatments. This work could identify drugs such as tocilizumab, resveratrol or adropin worth moving into human trials. It also builds a rigorous preclinical testing model for SAH drugs. For people with narrowed brain arteries, the clinical trial may establish more effective blood-thinning therapy to prevent stroke and vascular death.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
START (Subarachnoid hemorrhage Translational Advanced Research pre-Trial) Network for Promising Novel Drug Testing
NIH · Jul 2026 – Jun 2031
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NIH · Sep 2021 – May 2028
Neurovascular protection by adropin in acute neural injury from subarachnoid hemorrhage
NIH · Aug 2022 – Jul 2027
Closest labs
Maxim Mokin
University of South Florida, FL·Medicine & Clinical Research
Test whether continuous bedside optical monitoring predicts outcomes after aneurysmal subarachnoid hemorrhage, measuring cerebral blood flow and an index of cerebrovascular autoregulation with pathlength resolved diffuse correlation spectroscopy throughout acute hospitalization.
Pooneh Bagher
University of Nebraska Medical Center, NE·Physiology
Determine whether hemoglobin alpha in artery-lining endothelial cells becomes glycated in a mouse model of diabetes, including at sites within its putative eNOS-binding domain.
Robert Campbell
Washington University in St Louis, MO·Medicine & Clinical Research
Determine how the mitochondrial calcium uniporter (MCU), the channel bringing calcium into mitochondria, controls platelet activation, procoagulant platelet formation and platelet-neutrophil aggregates, including signaling through the enzyme Syk.
The school
University of Florida: 65 labs on PI Pages, $1.3B a year on research, 795 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.